Literature DB >> 14461382

The localization of in vivo bound complement in tissue section.

P J LACHMANN, H J MULLER-EBERHARD, H G KUNKEL, F PARONETTO.   

Abstract

A technique has been described for the demonstration of a human complement component by an immunofluorescent method. The component detected is beta(1C)-globulin, a moiety of the third complement component, which has previously been obtained in pure form and to which a specific antiserum has been prepared. It has been shown in a model system that the binding of beta(1C)-globulin as shown by immunofluorescence is strictly equivalent to complement fixation as assessed by standard serological methods. This technique has been applied to the detection of in vivo bound complement in pathological human tissues. It was found that in vivo complement binding occurs in the lesions of several human diseases, but not elsewhere in the same tissues. In a rather limited survey of diseases that has been carried out, in vivo complement binding was found particularly in systemic L.E., various nephritides, and amyloidosis, as well as in single cases of some other diseases. The spectrum of in vivo complement binding has been compared with that of gamma-globulin binding (7S and 19S types) and with the demonstration of in vitro complement fixation and rheumatoid factor fixation. It was distinct from each of these. Rheumatoid factor fixation, detected by anti-19S antiserum showed promise as a method for the detection of antigen-antibody complexes and aggregated gamma-globulin in tissue sections. The interpretation of these findings in regard to the nature of the binding sites, and their possible significance in regard to pathogenic mechanisms have been discussed.

Entities:  

Keywords:  COMPLEMENT/chemistry

Mesh:

Substances:

Year:  1962        PMID: 14461382      PMCID: PMC2137475          DOI: 10.1084/jem.115.1.63

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Superiority of fluorescein isothiocyanate (Riggs) for fluorescent-antibody technic with a modification of its application.

Authors:  J D MARSHALL; W C EVELAND; C W SMITH
Journal:  Proc Soc Exp Biol Med       Date:  1958 Aug-Sep

2.  Isolation of a thermolabile serum protein which precipitates gamma-globulin aggregates and participates in immune hemolysis.

Authors:  H J MULLER-EBERHARD; H G KUNKEL
Journal:  Proc Soc Exp Biol Med       Date:  1961-02

3.  Studies of aggregated gamma-globulin. I. Sedimentation, electrophoretic and anticomplementary properties.

Authors:  C L CHRISTIAN
Journal:  J Immunol       Date:  1960-01       Impact factor: 5.422

4.  Localization of gamma-globulin in the diseased kidney.

Authors:  P FREEDMAN; J H PETERS; R M KARK
Journal:  Arch Intern Med       Date:  1960-04

5.  Analytical pathology. III. New observations on the pathogenesis of glomerulonephritis, lipid nephrosis, periarteritis nodosa, and secondary amyloidosis in man.

Authors:  R C MELLORS; L G ORTEGA
Journal:  Am J Pathol       Date:  1956 May-Jun       Impact factor: 4.307

6.  Pathogenesis of serum sickness.

Authors:  F J DIXON; J J VAZQUEZ; W O WEIGLE; C G COCHRANE
Journal:  AMA Arch Pathol       Date:  1958-01

7.  Isolation and description of proteins related to the human complement system.

Authors:  H J MULLER-EBERHARD
Journal:  Acta Soc Med Ups       Date:  1961

8.  SITES OF FORMATION OF IMMUNE GLOBULINS AND OF A COMPONENT OF C'(3): I. A NEW TECHNIQUE FOR THE DEMONSTRATION OF THE SYNTHESIS OF INDIVIDUAL SERUM PROTEINS BY TISSUES IN VITRO.

Authors:  G M Hochwald; G J Thorbecke; R Asofsky
Journal:  J Exp Med       Date:  1961-09-30       Impact factor: 14.307

9.  Studies on immune cellular injury. I. Cytotoxic effects of antibody and complement.

Authors:  A ROSS; I H LEPOW
Journal:  J Exp Med       Date:  1960-12-01       Impact factor: 14.307

10.  Isolation and characterization of two beta1-glycoproteins of human serum.

Authors:  H J MULLER-EBERHARD; U NILSSON; T ARONSSON
Journal:  J Exp Med       Date:  1960-02-01       Impact factor: 14.307

View more
  72 in total

1.  SERUM LEVELS OF BETA-1C GLOBULIN, A COMPLEMENT COMPONENT, IN THE NEPHRITIDES, LIPOID NEPHROSIS, AND OTHER CONDITIONS.

Authors:  C D WEST; J D NORTHWAY; N C DAVIS
Journal:  J Clin Invest       Date:  1964-08       Impact factor: 14.808

2.  THE CYTOPLASMIC AUTO-ANTIGEN OF THE HUMAN THYROID. I. IMMUNOLOGICAL AND BIOCHEMICAL CHARACTERISTICS.

Authors:  I M ROITT; N R LING; D DONIACH; K G COUCHMAN
Journal:  Immunology       Date:  1964-07       Impact factor: 7.397

3.  HEMOLYTIC COMPLEMENT IN SYNOVIAL FLUID.

Authors:  T J PEKIN; N J ZVAIFLER
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

4.  IDENTIFICATION OF THE COMPONENTS OF COMPLEMENT PARTICIPATING IN THE ANTIGLOBULIN REACTION.

Authors:  M HARBOE; H J MUELLER-EBERHARD; H FUDENBERG; M J POLLY; P L MOLLISON
Journal:  Immunology       Date:  1963-07       Impact factor: 7.397

5.  Complement fixation in diseased tissues. II. Fixation of guinea pig complement in renal lesions of systemic lupus erythematosus.

Authors:  P M BURKHOLDER
Journal:  Am J Pathol       Date:  1963-02       Impact factor: 4.307

6.  ELECTRON MICROSCOPIC STUDIES OF AMYLOID FIBRILS WITH FERRITINCONJUGATED ANTIBODY.

Authors:  W E PAUL; A S COHEN
Journal:  Am J Pathol       Date:  1963-10       Impact factor: 4.307

7.  THE EFFECTS OF ANTIBODIES ON CELLS. I. BIOCHEMICAL AND HISTOCHEMICAL EFFECTS OF ANTIBODIES AND COMPLEMENT ON ASCITES TUMOUR CELLS.

Authors:  D C DUMONDE; L BITENSKY; G J CUNNINGHAM; J CHAYEN
Journal:  Immunology       Date:  1965-01       Impact factor: 7.397

8.  IMMUNOFLUORESCENT STUDIES IN ADULT CELIAC DISEASE.

Authors:  W RUBIN; A S FAUCI; S F MARVIN; M H SLEISENGER; G H JEFRIES
Journal:  J Clin Invest       Date:  1965-03       Impact factor: 14.808

9.  IMMUNOCYTOCHEMICAL OBSERVATIONS ON THE VASCULAR NECROSIS AND RENAL GLOMERULAR LESIONS OF MALIGNANT NEPHROSCLEROSIS.

Authors:  F PARONETTO
Journal:  Am J Pathol       Date:  1965-06       Impact factor: 4.307

10.  Systemic lupus erythematosus. Cryoprecipitation of sera.

Authors:  C L CHRISTIAN; W B HATFIELD; P H CHASE
Journal:  J Clin Invest       Date:  1963-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.